Insulet Corporation and Eli Lilly and Company have entered into a collaboration under which Insulet will develop a new version of the OmniPod insulin pump designed to deliver Humulin R U-500 insulin.
R U-500 insulin is a regular U-500 insulin human injection, a concentrated form of insulin used by people with highly insulin resistant type 2 diabetes.
The partnership focuses on the clinical development program to determine the safety and efficacy of the combined delivery system.
Insulet president and CEO Duane DeSisto said that the insulin pump for Humulin R U-500 insulin is designed to bring the advantages of the OmniPod System to people with highly insulin resistant type 2 diabetes.
"The tubeless design of the OmniPod insulin pump provides freedom and ease of use for tens of thousands of people living with diabetes today," DeSisto added.
